Name game
Tags: PHARMACEUTICAL industry
Related Articles
- Product news. // Medical Marketing & Media;Aug97, Vol. 32 Issue 8, p30
Reports on developments in the pharmaceutical industry as of August 1997. Includes Jones Medical Industries's acquisition of several drugs from SmithKline Beecham; Alza Corp.'s acquisition of the Mycelex Troche product from Bayer AG; Recommendation for the approval of Neurex Corp.'s fenoldopam...
- Report: More foreign surveillance needed. Dickinson, James G. // Medical Marketing & Media;Sep97, Vol. 32 Issue 9, p28
Cites a report from the US Food and Drug Administration which underscored the need to increase post-approval routine surveillance inspections at foreign pharmaceutical facilities. Importance of background checks on pharmaceutical firm's compliance status; Recommendation of a risk-based approach...
- Scott-Levin lists top firms in retail Rx sales. // Medical Marketing & Media;Oct97, Vol. 32 Issue 10, p24
Lists the top five corporations in second-quarter pharmacy retail sales for 1997 in the United States. Rise of market for retail pharmacy sales; Drugs that posted increase in sales.
- IMS America Business watch: First half of 1997 review. // Medical Marketing & Media;Oct97, Vol. 32 Issue 10, p74
Provides an overview on the significant increase in growth sales of pharmaceutical products for the first half of 1997 in the United States. Factors driving the growth; US pharmaceutical market sales; Growth of total prescriptions; Channel distribution of dispensed prescriptions; Leading...
- Business update. // Medical Marketing & Media;Nov97, Vol. 32 Issue 11, p102
Focuses on several developments concerning the pharmaceutical industry as of November 1997. Includes Professional Detailing's contract with Astra Merck Inc.; ACG Communications' acquisition of Signa Programs; Dorland Sweeney Jones Health Communications' opening of a California office;...
- Another year's smooth sailing ahead. Gerber, Steven B. // Medical Marketing & Media;Feb98, Vol. 33 Issue 2, p34
Examines trends that shaped the status of the pharmaceutical industry of the United States in 1997. Likely reaction of the managed care industry to its eroding profitability; Adverse publicity related to the heart valve complications that result from using fen-phen combinations; US Food and...
- Promotion dollars up; aimed mostly at providers in 1997. // Medical Marketing & Media;May98, Vol. 33 Issue 5, p22
States that the drug industry in the United States spent $8.8 billion in promotional efforts for 1997. How the money was spent; Percentage of money spent on the promotions to physicians; Reference to an increase in sales representatives in the drug industry; Comments from Myron Holubiak,...
- The PMAC code of marketing practices: Time for improvement? Desjardins, Jean G. // CMAJ: Canadian Medical Association Journal;02/01/97, Vol. 156 Issue 3, p363
Presents proposals for reforms to aid the Pharmaceutical Manufacturers Association of Canada (PMAC) adapt its Code of Marketing Practices to changes. Conflict between the promotional activities of drug companies and ethical standards; Need for the PMAC to improve its Code of Marketing Practices.
- Nurture home fires. Gopal, Kevin // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p36
Focuses on the performance of the German pharmaceutical industry in 1996 according to the research firm Verband Forschender Arzneimittelhersteller (VFA). Research and development updates; Spending and personnel numbers; Financial gains and loses; Total investment amounting to 1.8 billion...
- Words of welcome. Gopal, Kevin // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p37
Announces the European Federation of Pharmaceutical Industries' Association's (EFPIA) opening of its membership to individual companies. Move as part of an initiative to restructure EFPIA; Efforts in providing a coherent and stronger representation of pharmaceutical companies in Europe; Mission...
